Correction (DOI:10.1016/j.jacc.2009.04.089);Regadenoson: A New Myocardial Stress Agent

Journal of the American College of Cardiology

Volumn 54, Issue 13, 2009, Pages 1123-1130

  Al Jaroudi, Wael ^a   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

adenosine; myocardial perfusion imaging; regadenoson; single photon emission computed tomography; stress testing

Indexed keywords

ADENOSINE; AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; DIPYRIDAMOLE; DOBUTAMINE; REGADENOSON; STEROID;

ASTHMA; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRONCHOSPASM; CARDIAC PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; EXERCISE TEST; FLUSHING; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART RATE; HEART STRESS; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; QT PROLONGATION; RECEPTOR AFFINITY; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; VASODILATATION;

EID: 70049109278     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.09.008     Document Type: Erratum

References (49)

1. Thom T., Haase N., Rosamond W., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Pharmacologic stress testing. In: Iskandrian A.E., and Garcia E.V. (Eds). Nuclear Cardiac Imaging: Principles and Applications. 4th edition (2008), Oxford University Press, New York, NY 293-315
3. Miyamoto M.I., Vernotico S.L., Majmundar H., and Thomas G.S. Pharmacologic stress myocardial perfusion imaging: a practical approach. J Nucl Cardiol 14 (2007) 250-255
4. Shryock J.C., and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79 (1997) 2-10
5. Deussen A., Lloyd H.G., and Schrader J. Contribution of S-adenosylhomocysteine to cardiac adenosine formation. J Mol Cell Cardiol 21 (1989) 773-782
6. Olah M.E., and Stiles G.L. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35 (1995) 581-606
7. Spicuzza L., Di Maria G., and Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmcol 533 (2006) 77-88
8. Auchampach J.A., and Bolli R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol 276 (1999) H1113-H1116
9. Press N.J., Gessi S., Borea P.A., and Polosa R. Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin Ther Pat 17 (2007) 979-991
10. Gao Z.G., and Jacobson K.A. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12 (2007) 479-492
11. Buhr C., Gossl M., Erbel R., and Eggebrecht H. Regadenoson in the detection of coronary artery disease. Vasc Health Risk Manag 4 (2008) 337-340
12. 2A adenosine receptor agonists. Am J Cardiol 94 (2004) 33D-40D
13. Cerqueira M.D. Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr Cardiol Rep 8 (2006) 119-122
14. 2A adenosine receptor. Nucleosides Nucleotides Nucleic Acids 20 (2001) 343-360
15. 2A receptor. Bioorg Med Chem Lett 12 (2002) 2935-2939
16. 2A agonists. J Pharmacol Exp Ther 298 (2001) 209-218
17. 2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 41 (2003) 132-139
18. Fan M., and Mustafa S.J. Adenosine-mediated bronchoconstriction and lung inflammation in an allergic mouse model. Pulm Pharmacol Ther 15 (2002) 147-155
19. 2A adenosine receptor reserve for coronary vasodilation. Circulation 98 (1998) 711-718
20. 2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 307 (2003) 182-189
21. 2A receptor agonist. J Cardiovasc Pharmacol 49 (2007) 369-375
22. 2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 316 (2006) 695-702
23. Hage F.G., Heo J., Franks B., et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 154 (2009) 771-776
24. Gordi T., Frohna P., Sun H.L., Wolff A., Belardinelli L., and Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 45 (2006) 1201-1212
25. Gordi T., Blackburn B., and Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 47 (2007) 825-833
26. 2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 14 (2007) 514-520
27. Gaemperli O., Schepis T., Koepfli P., et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 51 (2008) 328-329
28. Zoghbi G.J., Htay T., Aqel R., Blackmon L., Heo J., and Iskandrian A.E. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol 47 (2006) 2296-2302
29. Reyes E., Loong C.Y., Harbinson M., Donovan J., Anagnostopoulos C., and Underwood S.R. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol 52 (2008) 2008-2016
30. Böttcher M., Czernin J., Sun K.T., Phelps M.E., and Schelbert H.R. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med 36 (1995) 2016-2021
31. 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 46 (2005) 2069-2075
32. Iskandrian A.E., Bateman T.M., Belardinelli L., et al., ADVANCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trials. J Nucl Cardiol 14 (2007) 645-658
33. 2a agonist regadenoson versus adenosine in myocardial perfusion imaging: integrated ADVANCE-MPI trial results. J Am Coll Cardiol Img 1 (2008) 307-316
34. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J., and CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 295 (2006) 1152-1160
35. Le Henanff A., Giraudeau B., Baron G., and Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 295 (2006) 1147-1151
36. Iskandrian A.E., Garcia E.V., and Faber T. Analysis of serial images: a challenge and an opportunity. J Nucl Cardiol 15 (2008) 23-26
37. Zhao G., Serpllion S., Shryock J., et al. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs. J Cardiovasc Pharmacol 52 (2008) 467-473
38. 2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 16 (2009) 63-72
39. Reyes E., Loong C.Y., Wechalekar K., Latus K., Anagnostopoulos C., and Underwood S.R. Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 14 (2007) 827-834
40. Fricke E., Esdorn E., Kammeier A., et al. Respiratory resistance of patients during cardiac stress testing with adenosine: is dyspnea a sign of bronchospasm?. J Nucl Cardiol 15 (2008) 94-99
41. Balan K.K., and Critchley M. Is the dyspnea during adenosine cardiac stress test caused by bronchospasm?. Am Heart J 142 (2001) 142-145
42. Global Strategy for Asthma Management and Prevention. Global Initiative Form Asthma Executive and Science Committees, 2006. http://www.ginasthma.org Accessed July 15, 2008
43. 2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 15 (2008) 329-336
44. Fabbri L., Pauwels R.A., Hurd S.S., and Gold Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. COPD 1 (2004) 105-141
45. 2Aagonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 15 (2008) 319-328
46. Arlington Medical Resources Inc., 2009. Nuclear Scans Monthly Shares. http://amr-data.com Accessed January 15, 2009
47. McGeoch R.J., and Oldroyd K.G. Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. Catheter Cardiovasc Interv 71 (2008) 198-204
48. 2A receptor agonist binodenoson for pharmacologic stress: results of a phase 3, randomized, double-blind, risk-stratified, active-controlled, crossover trial. Abstract 409-5. Paper presented at: Late-Breaking Trials, ACC Scientific Sessions; March 29 to April 1, 2008; Chicago, IL.
49. 2A adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation 104 (2001) 1181-1187